Under Diagnosis and Over Diagnosis of Prostate Cancer in a Screening Population With Serum PSA 2 to 10 ng/ml
- 1 July 2007
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 178 (1) , 93-97
Abstract
Since the implementation of widespread serum total prostate specific antigen based screening, the risk of prostate cancer over diagnosis has become a concern. We evaluated the amount of possible over and under diagnosis of prostate cancer in an asymptomatic screening population with a total prostate specific antigen of 2.0 to 3.9 (lower range) and 4.0 to 10.0 ng/ml (higher range). A total of 680 patients with prostate cancer were included. Possible over diagnosis was defined as Gleason score less than 7, pathological stage pT2a and negative surgical margins. Under diagnosis was defined as pathological stage pT3 or greater, or positive surgical margins. Furthermore, insignificant tumors according to the Epstein criteria were evaluated in a small subset of patients for whom cancer volume information was available. In the lower and higher total prostate specific antigen ranges there was an over diagnosis rate of 19.7% and 16.5%, and an under diagnosis rate of 18.9%* and 36.7%, respectively (p<0.05). In the prostate specific antigen range of 2.0 to 10.0 ng/ml combined the rates of over and under diagnosis were 17.6% and 30.3%, respectively. In addition, 8.7% of tumors with total prostate specific antigen 2.0 to 10.0 ng/ml met the Epstein criteria for insignificance. These data show that the reported estimates of over diagnosis in the low total prostate specific antigen group are exaggerated in a screening population. Using our criteria prostate cancer under diagnosis occurs more frequently than over diagnosis in the total prostate specific antigen range of 4.0 to 10 ng/ml.Keywords
This publication has 18 references indexed in Scilit:
- PROSTATE CANCER DETECTION IN MEN WITH PROSTATE SPECIFIC ANTIGEN 4 TO 10 NG/ML USING A COMBINED APPROACH OF CONTRAST ENHANCED COLOR DOPPLER TARGETED AND SYSTEMATIC BIOPSYJournal of Urology, 2005
- Characteristics of prostate cancers detected at low PSA levelsThe Prostate, 2003
- Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence TrendsJNCI: Journal of the National Cancer Institute, 2002
- Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, AustriaUrology, 2001
- Causes of Death in Elderly Prostate Cancer Patients and in a Comparison Nonprostate Cancer CohortJNCI: Journal of the National Cancer Institute, 2000
- Cancer Surveillance Series: Interpreting Trends in Prostate Cancer Part II: Cause of Death Misclassification and the Recent Rise and Fall in Prostate Cancer MortalityJNCI: Journal of the National Cancer Institute, 1999
- Cancer Surveillance Series: Interpreting Trends in Prostate Cancer Part III: Quantifying the Link Between Population Prostate-Specific Antigen Testing and Recent Declines in Prostate Cancer MortalityJNCI: Journal of the National Cancer Institute, 1999
- Serum prostate‐specific antigen in a community‐based population of healthy Japanese men: lower values than for similarly aged white menBritish Journal of Urology, 1995
- Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer1994
- Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening1993